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ORIGINAL PAPER 
NUTRITIONAL THERAPIES FOR ULCERATIVE 
COLITIS: LITERATURE REVIEW, CHART 
REVIEW STUDY, AND FUTURE RESEARCH 
Joel S. Edman. DSc. William H. Williams, PhD. and Robert C. Atkins, MD 
Joel S. Edman is a nutritional consultant in Hartsdale, NY, and 
the former director of nutrition at the Atkins Center for 
Complementary Medicine in New York City. William H. 
Williams is professor of mathematics and statistics at Hunter 
College, City University of New York. Robert C. Atkins is med- 
ical director of the Atkins Center for Complementary Medicine. 
Few clinical studies suggest a significant influence of diet or 
nutritional supplementation 011 ulcerative colitis. One reason is that 
ulcerative colitis, like many chronic diseases, is multifactorial. This 
article will describe and rePic11• the relevant literature on ulcerative 
colitis, including studies of (1) diet and intravenous therapy. (2) 
nutritional status and nutritional supplementation, and (3) bowel 
flora and immune function and their influences. Also, results of a ret- 
respective char/ rel'ie11• study that ll'as done at a complementary med- 
icine office will be presented. Finally. suggestions for future research 
will be discussed based 011 a nutritional model of ulcerative colitis. 
Taken together, it is hoped that these areas wilt clar~6· the current sta- 
tus of ulcerative colitis research and promote the types of investiga- 
tions that are necessary to establish tlie validity of nutritional 
injluences on ulcerative colitis as well as the mechanisms that are 
involved. (A/tern Ther Health Med. 2000:6(1):55-63) 
I
t is surprising that so few clinical studies have found that 
di~tary '". nutritional _factors significantly influence ulcer- 
ative colitis (UC). ' It is noteworthy. however, that a range 
of factors have been researched including dietary compo- 
nents such as refined sugars, allergenic foods,',- and fast 
foods,' as well as nutritional supplement effects from fish oil,' 
zinc,' glutamine," folate,"' and a-tocopherolquinone." 
Investigators have also examined the interrelationships between 
bowel flora and UC, including factors such as flora changes,":" 
endotoxernia." and supplementation effects with Lactobacillus 
species." These studies, combined with a review of UC, 1" suggest 
that nutritional influences on UC are multifactorial. 
The multifactorial nature ofUC--common in many chronic 
disorders-helps to explain why few clinical studies have suggest- 
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ed beneficial effects from nutritional approaches, The unfortunate 
result, however, is that many practitioners in medicine do not 
accept the importance or benefit of diet and nutritional supple- 
mentation, and those who do must develop empirical therapies 
based on what patients are willing to do and what seems to be 
helpful. Although this approach has been effective for many 
patients, it is now necessary for researchers and complementary 
and alternative medicine (CAM) practitioners to substantiate these 
significant effects through well-designed prospective research. In 
addition, these investigations should clarify involved mechanisms 
and establish criteria for the use of specific nutritional guidelines, 
With these points in mind, this article will (1) review and dis- 
cuss the relevant literature concerning UC, (2) describe a chart 
review study that was performed in an outpatient complementary 
medicine office, and (3) discuss the necessary future research 
based on a proposed nutritional model for UC. 
ULCERATIVE COLITIS LITERATURE REVIEW 
Diet and Intravenous Therapy 
In research on diets that were followed prior to acute exacer- 
bations of UC, it has been shown that individuals eating higher 
levels of sugar,31• fast food,' and bread" were at greater risk. 
Investigations of food sensitivity or allergy showed elevated levels 
of cow's milk antibodies in UC patients in one study," and in 
another study' 70% of subjects reported concomitant symptoms 
that were judged to be possibly allergic. A 1997 study of self- 
reported food intolerance found that 64% of UC patients believed 
they developed specific UC symptoms from one or more foods." 
A more thorough review of dairy allergy or sensitivity in inflam- 
matory bowel disease (IBD) suggests multiple potential reactions 
that may include sensitivity to dairy proteins, lactose intolerance, 
and possible intolerance to long-chain triacylglycerol content." 
A clinical trial of a dairy-free diet showed a decreased relapse 
rate in UC patients.' This effect was more pronounced in those 
patients with a history of UC of less than 3 years. This study esti- 
mated that approximately 20% of patients may benefit from this 
restriction. An unconfirmed report suggested a correlation 
between responses to rectally injected antigens and disease 
improvement with dietary antigen withdrawal." I lowever, no stud- 
ies in the last 30 years have examined therapeutic influences of diet 
in UC. and other findings have not confirmed pre-illness diet or 
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allergenic effects that influence UC development or treatment.' '"; 
In contrast to UC, however, dietary studies of Crohn 's dis- 
ease have consistently found increased levels of sugar intake.':':" 
As a result, a few more studies of Crohn 's disease have explored 
therapeutic dietary effects. One study found that a sugar-free 
diet significantly reduced relapse rates," whereas another did 
not." A third investigation found that it was the hypoallergenic 
or exclusion diet that produced the benefits for ongoing patients 
and not the sugar-free diet." More consistent dietary effects may 
be observed in Crohn 's disease compared with UC, because 
dietary sugars and antigenic proteins may be more likely to 
reach involved intestinal mucosa and gut-associated lymphatic 
tissues that may influence mechanisms of disease activity. 
Investigations of intravenous therapy as a primary treat- 
ment for UC among hospitalized patients have examined the 
extent to which total parenteral nutrition (TPN), bowel rest, and 
small amounts of intravenous medication might be helpful. 11 '' 
One study" found that the severity of inflammation and the 
amount of colonic involvement affected whether the intravenous 
therapy was helpful in promoting remission. Less severity of dis- 
ease and less involvement was associated with more frequent 
short-term benefit, even though no effect on the relapse time or 
long-term prognosis was found. These 2 factors may therefore be 
important determinants for evaluating the success of nutritional 
factors and therapies, and may help to explain nutritional 
research inconsistencies. This TPN research also suggests that 
the level of disease activity and colonic involvement should be 
taken into account in future research, and that long-term studies 
are required to examine maintenance of remission. 
Nutritional Status and Nutritional Supplementation 
The chronic symptoms of UC, such as diarrhea, bloating, 
pain, and blood loss, as well as nutrient-drug interactions, sug- 
gest that nutritional deficiency might be common and have a 
role in UC pathology; however, studies generally have not found 
this to be the case. Folate deficiency was observed in one large 
study of chronic JBD patients," with anti-folate effects of sul- 
fasalazine having a significant effect." In addition, a study of col- 
orectal cancer and IBO showed a significantly lower level of 
serum retinal in UC patients compared with controls." Other 
studies suggest that UC patients may have subclinical or clinical 
deficiency of zinc, magnesium. calcium. and/or iron, especially 
with greater severity of disease.":" Finally, research on UC 
mucosa samples have shown altered ascorbic acid status," 
decreased antioxidant defenses," and low coenzyme A activity 
despite normal pantothenic acid levels.":" 
Few clinical studies examining the effects of nutritional sup- 
plementation have been done in UC. Probably the most significant 
investigation evaluated the influence of fish oil on UC and 
observed anti-inflammatory effects that may have derived from 
decreased leukotriene 84 levels.' This result was accompanied by 
improved histology indices and significant weight gain. A sub- 
group on prednisone also showed a nonsignificant average 
decrease from 12.9 mg/d to 6.1 mg/d. Only modest clinical 
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improvements were noted. however. so researchers concluded that 
fish oil could not be recommended as a simple treatment for UC. 
Another example of "nutritional supplementation" benefit 
was illustrated in a clinical study of distal UC in which butyrate 
enemas were found to significantly reduce stool frequency and 
bleeding as well as improve endoscopic scores and histologic mea- 
sures of inflammation." Butyrate is the primary energy substrate 
for colonocytes and its use was the likely mechanism through 
which significant benefit was produced. A related study showed 
that butyrate oxidation is impaired even in quiescent UC." 
The amino acid glutamine may also be beneficial for UC 
because it is also an energy substrate for colonocytes, though to a 
significantly lesser extent." Interestingly, an animal model of UC 
found that glutamine supplementation significantly decreased 
portal vein endotoxin levels"'-this may be another potential 
mechanism of benefit. This effect may have been explained by an 
investigation of glutamine-supplemented TPN that found a signifi- 
cant increase in biliary secretory immunoglobulin (lg) A.'" A fur- 
ther study showed that oral glutamine had more beneficial effects 
on secretory lgA than did intravenous glutarnine," suggesting a 
localized effect that might be derived from oral supplementation. 
A case-control study" of folate supplementation in UC 
showed a decrease in the incidence of dysplasia and cancer. 
Whereas several biologically plausible mechanisms were men- 
tioned in this study, one involved cell replication processes such 
as methylation pathways, purine synthesis, and DNA formation. 
A related clinical study" suggested that after 6 months of supple- 
mentation with 10000 µg of folate per day, significant increases 
in methylation pathways were found. It also may be plausible 
that folate status and function as well as cell replication and 
turnover could influence UC pathology. If this were true, argu- 
ments could be made for an effect of vitamin A and zinc because 
they may also influence cell replication. Interestingly, these 
nutrients also have immune effects, suggesting the potential for 
dual mechanisms in UC. Zinc supplementation in a double-blind 
study" of UC, however, was not found to significantly influence 
UC treatment, though this was a short-term study and there may 
have been a trend toward some benefit. 
Flora Composition, Immune Function, 
and Associated Influences 
Although there have been no highly significant studies 
showing an influence of bowel flora in UC, some research sup- 
ports several potential mechanisms by which flora may be 
important. For example, one study of mucosa-associated 
microflora in active UC compared to those with inactive disease 
showed significantly reduced counts of total flora, obligate 
anaerobes (eg. bifidobacteria), facultative organisms, and 
microaerobes (eg, lactobacilli)." The differences were also more 
significant in patients suffering their first UC attack compared to 
those with relapses. Although other studies have found associa- 
tions between UC and Escherichia coli.?" this study found£ coli 
less frequently and in smaller amounts. This study further sug- 
gested that other species found-such as bacteroides as well as 
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aerobic and anaerobic gram-positive cocci-were more common 
and might be promising candidates for potential influences in 
future UC research. A more thorough discussion of this area of 
investigation can be found elsewhere." 
The possibility of influencing bowel flora was suggested by 
a case report of UC showing beneficial results from supplernen- 
tation with rx-tocopberolquinone. in which the benefits were 
thought to have been produced from bowel flora effects.' 
In addition, more general probiotic "nutritional supplernenta- 
tion ·· research has shown the following: 
• supplementing with freeze-dried Lactobacillus casei GG 
reduced the susceptibility of subjects to traveler's diarrhea" 
• Lactobacillus GG yogurt reduced antibiotic-associated 
diarrhea" 
• a milk concentrate of Lactobacillus GG effectively treated 
relapsing Clostridium difficile colitis" 
• Lactobacillus GG significantly benefited pouchitis. a com- 
plication ofileal reservoir surgery in UC patients who have had a 
proctocolectorny" 
Possible mechanisms by which probiotic supplementation may 
be beneficial include increased gut immune responses" and 
decreased intestinal permeability." 
Another potentially important aspect of bowel flora influ- 
ence was shown in a clinical study of 25 UC patients in which it 
was determined that 88% had systemic endotoxemia, which pos- 
itively correlated with anatomic extent of disease and disease 
activity." Other studies":" have also found endotoxemia in UC 
and its correlation with disease activity. 
Part of the difficulty in assessing bowel flora effect comes 
not only from the significant variety of microflora species pre· 
sent in the gut, but also from the range and complexity of 
immunological measures and mediators that may suggest 
immune reactivity or mediate UC pathology, For example, there 
is evidence of circulating antibodies to bacterial. dietary, and 
self-antigens in UC, especially of the lgG subtype. In addition, 
increased intestinal permeability has been reported in 180, 
though this has been better documented in Crohn 's disease than 
in UC."'With regard to the lgG subtype of immunoglobulins 
found in UC, it is involved with complement activation that may 
mediate acute UC episodes." As for relevant cellular immunity 
responses, one study" showed that IBO mesenteric lymph node 
mononuclear cell responses (gut-associated lymphatic tissue 
cells) were generally greater to most flora antigens than they 
were to peripheral blood mononuclear cells, which were often 
undetectable. 
Whereas a discussion of the immunopathological aspects of 
UC are beyond the scope of this article, a more thorough review 
may be found elsewhere." This area is important, however, to the 
further understanding of nutritional and bowel flora influences in 
UC because this is where some specific mechanisms will be found. 
Future nutritional researchers will need to monitor general UC 
research to evaluate these investigations, and future nutritional 
research must include some of these immunological measures. 
In summary. there is a wide range of nutritional and medical 
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research of UC that has examined dietary factors, nutritional sta- 
tus. nutritional supplement effects, flora composition and effects, 
immunological factors. and intestinal factors. A concerted effort 
is now required to develop comprehensive nutritional protocols 
that can be shown to produce consistent benefits and provide 
clarification of involved mechanisms. The following retrospective 
chart review study illustrates the type of work that is required. 
CHART REVIEW STUDY 
A retrospective chart review study was conducted of24 con- 
secutive UC patients who presented to the Atkins Center for 
Complementary Medicine in New York, NY. Treatment empha- 
sized a comprehensive nutritional regimen including a sugar· 
free hypoallergenic diet and nutritional supplementation. 
Methods 
Subjects were included in this study who presented for 
treatment of UC between March 10, 1992. and January 20, 1995. 
All subjects had at least 2 follow-up appointments to monitor 
compliance with dietary and nutritional supplementation rec- 
ommendations, and to assess disease status through reported 
symptoms and medication dosage changes. Exclusion criteria 
were as follows: 
• inadequate follow-up visits (9 patients) 
• aged more than 70 years (7 patients) 
• other major illnesses (3 patients) 
• noncompliance (2 patients) 
• medical complications during treatment (2 patients) 
Twenty-four subjects (15 male, 9 female) were enrolled in 
the study. At time of presentation. subjects were aged 15 to 67 
years (average. 41.3 years). Although all subjects sought UC 
treatment, 14 (58.3%) specifically reported having colonoscopic 
and/or sigmoidoscopic tests done by previous physicians to con· 
firm their diagnosis. At presentation, 17 subjects were on 1 or 
more medications. Eight patients were on sulfasalazine (dose 
range. 1000-5000 mg/d), 7 were on prednisone (dose range, 2.5· 
25 rng/d), 5 were on Dipentum (olsalazine sodium) (dose range. 
500-2000 mg/d), 3 were on Asacol (mesalarnine) (dose range, 
600-2400 mg/d), 1 was on lmuran (azathioprine) (50 mg/d), 1 
was on cyclosporine (200 mg/d), 4 were having cortisone ene- 
mas (1-2 times per day), 1 was having a lidocaine gel enema (2 
times per day), and 1 was on lmodium (loperamide hydrochlo- 
ride) (2 times per day). The other 7 subjects had reported being 
on a course of prednisone and/or sulfasalazine at least once 
before their visit. Symptoms at presentation included the follow· 
ing: 19 with diarrhea (79.2%). 13 with bleeding (54.2%), JO with 
pain or cramping (41.7%). 10 with mucus (41.7%), 5 with bloat· 
ing (20.8%). and 4 with gas (16. 7%). Subjects reportedly had 
their CC diagnosis from 2 months to 20 years (average, 6.2 
years). They were followed in this study from 1 to 26 months 
(average, 7.2 months). Monitoring of subject progress and data 
collection ended July 31, 1995. 
At the first visit after a complete medical work-up that 
included a history, physical examination, and comprehensive 
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blood analysis. 1 of 2 staff medical doctors prescribed a specific 
nutritional regimen. The subjects then met with a clinical nutri- 
tionist who carefully explained a sugar-free, hypoallergenic diet. 
All forms of sugar and foods that contained sugar were excluded 
from the patients' diet. Allergenic foods such as dairy products. 
peanuts, citrus, and yeast were excluded from all subjects' diets. 
In addition, some patients had food sensitivity testing that sug- 
gested a further restriction for wheat (7 subjects) and corn (3 
subjects). 
Nine subjects had stool and rectal mucosa samples collect- 
ed for microbial and parasite analyses (Great Smokies Diag- 
nostic Laboratories, Asheville. NC). Parasite evaluations used 
enzyme immunoassays with monoclonal antibodies, immune- 
florescence assays with monoclonal antibodies. and computer- 
enhanced video microscopy. The presence of possible pathogens 
was assayed by culture techniques using standard media and 
incubation guidelines, and the Vitek system for colorimetric 
identification of bacteria. 
Initial nutritional supplementation included (1) a multivi- 
tamin and mineral supplement (2-6 tablets per day) (Table 1); 
(2) an oil formula containing co-3 and co-6 fatty acids derived 
from fish oil (400 mg), borage oil (400 mg), and flax oil 
(400 mg) (3-8 softgels per day) (Table 1), with 2 subjects 
instead taking separate fish oil and borage oil supplements; 
and (3) a probiotic. For the probiotic, 12 subjects took a 
Bacillus laterosporus supplement (2-3 capsules per day, 280 mg 
each) and 12 subjects Look a Lactobacillus formula containing L 
acidophilus, L bifidus, and L bulgaricus strains (2-8 capsules per 
day, approximately 500000 spores each). In addition, 22 of 24 
subjects took large doses of folate (20-60 mg/ d), 22 of 24 sub- 
jects took pantethine (450-900 mg/d), 20 of 24 subjects Look 
beta carotene (25 000-75 000 l U/ d). and 18 of 24 subjects took 
vitamin A (20000-40000 IU/d). In addition, 7 subjects took 
calcium carbonate (500-1000 mg/d) and 3 subjects took extra 
zinc (30-60 mg/d). Also, some subjects received supplements 
for specific symptoms or disorders unrelated Lo UC and 4 sub- 
jects received intravenous nutrients. Finally, it should be noted 
that glutamine was not a significant part of the regimen, 
because recognition of its effects in intestinal function is more 
recent; only 3 subjects took it toward the end of their study 
participation. 
A sign Lest was used for evaluating clinical improvement in 
medicated and nonmedicated subjects." Medication dose 
changes in subject subsets were assessed by paired I tests and by 
nonparametric Wilcoxon rank sum Lest. 
Results 
Eighteen of 24 subjects (75%) with UC improved on a 
sugar-free hypoallergenic diet with nutritional supplementation 
(Table 2). This included 12 of 17 subjects on various UC medica- 
tions at presentation who had symptomatic improvement 
and/or medication reduction, and 6 of7 nonmedicated subjects 
who had symptomatic improvement. Using a simple sign test 
and a 1-sided alternative hypothesis against the null hypothesis 
L~ 
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TABLE 1 ;-.;'utrilional supplementation among <tudy participants 
:'\utrient 
:\1ulti\ itamin and mineral composition" 
Per tablet Total 
Vitamin A 200 IL' 400-1200 IL! 
Beta carotene 500 Ill 1000-3000 Ill 
Vitamin D2 15 IL' 30-90 Ill 
Thiamine 5 mg 10-30 mg 
Riboflavin 4 mg 8-24 mo " Niacin 2 mg 4-12 mg 
:'\iacinamide 5mg 10-30 mg 
Pantethine 25 mg 50-150 mg 
Pantothenic acid 25 mg 50-150 mg 
Pyridoxine 20 mg 40-120 mg 
Pyridoxal 5 phosphate 2 mg 4-12 Ill" D 
Cyanocobalamin 30 pg 60-180 pg 
Folate JOO µg 200-600 pg 
Biotin 75 pg 150-450 pg 
Choline 100 mg 200-600 mg 
Inositol 80mg 160-480 mg 
Para-aminobenzoic acid 100mg 200-600 mg 
Ascorbate 120 mg 240-720 mg 
Citruv bioflavinoids 150mg 300-900 mg 
Alpha-rocopherol 20 ll1 40-120 Ill 
Copper 200 pg 400-1200 pg 
Magnesium 8mg 16-48 mg 
Manganese 4 mg 8-24 mg 
Chromium 50 pg 100-300 µg 
Molybdenum ]() pg 20-60 pg 
Vanadium 15 pg 30-90 µg 
Selenium 40 pg 80-240 pg 
Octacosanol 150pg 300-900 µg 
N-acetykysteine 20 µg 40-120 µg 
Reduced glutathione 5mg 10-:lO µg 
Oil formula compositiont 
ratty acid Per softgel Total 
Oleic acid I52 mg 456-1216 mg 
Linoleic acid 180 mg 540-1440 mg 
Gamma linolenic acid 96 mg 288-768 mg 
Alpha linolenir acid 164 mg 492-1312 mg 
Eicosapentaenoic acid 120 mg :l60-960 mg 
Docosahexaenoic acid 80 mg 240-640 mg 
* Subjects look 2 lo 6 tablets per day. 
t Subjects took 3 to 8 ,oftgeb per day: also contained 5 IL' ofvitarnin E per ,oft gel. 
(ie, that the procedures were equally likely to help the subjects 
or not help them), the P value associated with 12 of 17 improve- 
ments was .015-a statistically significant result. In addition, a 
simple statistical sign test demonstrated that the treatment. 
which resulted in O of the 7 non medicated subjects deteriorat- 
ing, was significant (P= .016). (Table 3 lists the specific symp- 
tom changes for medicated and nonmedicated subjects.) 
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TABLE 2 Nutritional regimen effects 25 
~ 
Medication Not improved eo 20 5 
status at ;-.:o. of ~ 
Same worse 0 15 presentation subjects Improved -0 " ~ 10 
On medication 17 12 2 __jJ ·c Off medication 7 6 1 ~ 5 Totals 24 18 3 
Beginning Ending 
There was a trend toward reducing subject prednisone dose 
during the study period, whereas the sulfasalazine dose was sig- 
nificantly lower. The prednisone dose decreased from 14.8 mg/d 
to 9.0 mg/d (Figure 1). Despite the small sample size, this 
decrease in prednisone was close to statistical significance. A l· 
sided, paired t test resulted in a P value of .065. Similarly, the 
nonparametric Wilcoxon rank sum test yielded a P value of .066. 
Sulfasalazine dose decreased significantly, from 2814 mg/d 
to 1375 mg/d (Figure 2). As measured by a number of statistical 
tests, this decrease in sulfasalazine was significant. A l-sided, 
TABLE 3 Specific symptom changes among medicated and non· 
medicated subjects 
Medicated subjects at presentation (n=17)* 
Not improved Developed 
(initially 
No. of not pre· 
Symptoms subjects Improved Same Worse sent) 
Diarrhea 13 7 3 3 0 
Bleeding 9 7 2 0 1 
Mucus 8 5 3 0 1 
Pain or cramps 7 4 2 1 1 
Bloating 4 3 1 0 0 
Gas 2 1 1 0 0 
Nonmedicated subjects at presentation (n = 7) 
Not improved 
No. of 
Symptoms subjects Improved Same \Vorse 
Diarrhea 6 6 0 0 
Bleeding 4 3 1 0 
Mucus 2 1 1 0 
Pain or cramps 3 3 0 0 
Bloating 1 1 0 0 
Gas 2 2 0 0 
* Eleven subjects reduced medication. S remained at initial levels. and l 
increased medication. 
FIGURE 1 Change in subject prednisone dose with 
nutritional regimen* (n=6, P=.065) 
* One outlier was excluded from the calculation. Study period ranged from 
l to 26 months. 
pooled t test yielded a P value of .028. Although a normal proba- 
bility plot showed no evidence of nonnormality, the nonpara· 
metric Wilcoxon rank sum test was also used to assess the 
treatment effects on subjects taking sulfasalazine. This test had a 
P value of .0004, which is highly significant. 
The prednisone analysis did not include 1 subject who was 
not controlled on the protocol and pursued further treatment 
elsewhere. This subject's presentation dose was 2.5 mg/d and 
the ending dose was 75 mg/d (more medication than the ending 
dose of the other 6 prednisone subjects combined). 
Five subjects improved sufficiently to allow discontinuation 
of their medication. Two of these subjects had to restart medica- 
tion again, though their symptoms were controlled at lower doses 
than at their initial presentation. The 3 remaining patients were 
controlled without medication at the end of the study period. 
Table 4 presents the results of a subset of subjects (9/24) 
with microflora analyses before treatment. As indicated, 2 of 9 
patients had a parasite and 3 of 9 had possible pathogens. In 
addition, 6 of 9 patients had imbalanced flora as indicated by 
5000 




FIGURE 2 Change in subject sulfasalazine dose 
with nutritional regimen* (n=8, P=.028) 
* Study period ranged from I to 26 months 
L ________, 
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inadequate amounts of Lactobacillus species and/or£ coli (5/9), 
and excessive amounts of Enterobacter cloacae, hemolytic E coli, 
and/or Morganel/a morganii (2/9). Unfortunately, no follow-up 
analyses were performed. 
DISCUSSION 
The results of this retrospective chart review study suggest 
that a dietary and nutritional supplementation regimen may sig- 
nificantly benefit UC patients. This study finding is based on sig- 
nificant improvements in symptoms and medication dosage 
needed to control symptoms. In the context offew positive clini- 
cal studies, these results suggest that a comprehensive therapeu- 
tic nutritional program will more likely help UC patients and 
produce more consistent study results than will a single dietary 
factor or nutritional supplement. Future research is necessary, 
however, to confirm these results, clarify the relationship 
TABLE 4 Microbial analysis in sample subset (n=9) 
Imbalanced flora 
Subject Possible 
No. Parasite pathogen Excess Inadequate 























between specific nutritional factors and UC, and further evaluate 
the possible multifactorial nutritional influence in this disorder. 
Also, because sulfasalazine is used for both treatment and main- 
tenance of remission in UC,05 longer-term studies are necessary 
to determine whether sulfasalazine reduction will adversely 
affect the relapse rate. 
These data are reported with the understanding that chart 
review studies include several weaknesses. Weaknesses in this 
study include the following: nutritional regimes varied by sub- 
ject, variations in duration of subjects' study period, self-report- 
ing of symptoms and lack of an objective disease activity index, 
potential for selective recording of symptom self-reports. possi- 
ble sample selection bias, lack of a control group, inability to 
draw conclusions concerning the relative importance of specific 
dietary guidelines followed and nutritional supplements taken, 
and inability to assess specific mechanisms involved. 
The sample selection bias resulted from the 11 subjects who 
were excluded from the study due to inadequate follow-up (n=9) 
or noncompliance (n=2). The often severe dietary restrictions 
and large requirement for supplement ingestion could have 
selected more highly motivated subjects. Therefore, the results 
may not be generalizable to all subjects with UC. 
This research does not meet the standards required to draw 
conclusions about the effects of nutritional therapies; however, it 
does illustrate important research parameters such as inclusion 
and exclusion criteria, the need for a standardized nutritional 
regimen, and the requirement for assessment of objective symp- 
tom scores and disease activity measures. These and other issues 
will be more thoroughly discussed in the following section. 
FUTURE RESEARCH 
Considerable additional research concerning nutritional 
influences on UC should be undertaken. First and foremost, 
there should be outcome-type research to show that nutritional 
approaches are beneficial. Such research should include an abili- 
ty to examine dietary and nutritional supplementation 
approaches both individually and as part of a combined treat- 
ment. More refined investigations of UC must clarify various 
aspects of the contributing factors. This research may be more 
clearly examined with the use of a model like the one in Figure 3. 
This model shows that dietary guidelines and nutritional supple- 
mentation may influence 2 primary categories: (1) bowel flora 
composition and related factors such as endotoxin secretion and 
colonization resistance, and, more importantly, (2) intestinal 
parameters at the cellular and tissue level as well as immunologi- 
cal measures that are integrated into both. This latter category 
includes a wide range ofhistologic measures and sigmoidoscopic 
indices as well as eicosanoid production, intestinal permeability, 
immune reactivity, and so on. These categories may then influ- 
ence systemic factors such as endotoxemia and liver detoxifica- 
tion-all of which combine to influence UC symptoms. 
Future investigations should include a prospective design; 
an adequate sample size; a control group; a standard diet and / 
L- -------------------------n-u-tr-i-ti_o_n_a_l _s,pplem,nt cegim,n; an adequate study Ieng] 
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objective measures of UC activity such as sigmoidoscopy scores, 
histology indices, disease activity indices, and relapse rates; and 
appropriate study designs that examine multifactorial disorders. 
In addition, it will be necessary to examine individual nutrition- 
al factors and their effect on some of the intermediary measures 
discussed in this article such as (1) intestinal factors (eg, cellular 
measures, mucosa! indices, and immunological parameters), (2) 
bowel flora composition and related factors, and (3) systemic 
factors (eg, endotoxemia and liver detoxification). These types of 
studies may show influences of these factors on UC measures, 
Dietary factors 
• Sugars 
• Food antigens 
• Others 
Nutritional supplements 












• Histology measures: 
Loss of polarity 
Mucin content of surface 
epithelium 
Denudation or erosion 
Superficial and deep 




• Inflammation and 
ulceration 
• Anatomic extent of 
disease 
• Intestinal permeability 




Bowel flora composition 
• Species types and amount 
• Toxic secretion 
• Colonization resistance 
• Bacterial fermentation/synthesis of short 
chain fatty acids 
• pH 
• Rule out parasites 
• Other flora influences 
• Impaired antioxidant defenses 
L Immunologic _] 
• Secretory lgA 
• Mesenteric lymph node mononuclear cell reactivity 
• Eicosanoid production 
• Other GALT functions and immunologic parameters 
Systemic effects 
• Endotoxemia, acute phase 
proteins, circulating TNF 
• Liver detoxification 
Ulcerative colitis symptoms 
• Bleeding • Bloating 
• Diarrhea • Pain and cramps 
• Mucus • Gas 
FIGURE 3 Multifactorial model of nutritional therapy in ulcerative colitis. GALT indicates gut-associated 
lymphoid tissue; TNF, tumor necrosis factor. 
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but they may not be large enough to affect clinical symptoms. 
Such studies may, however, help to identify more subtle relation- 
ships, of which there may be several. 
Examples of some specific intermediary investigations in UC 
would include the following: 
• the effects of variation of dietary macronutrients, and sugar 
content on bowel flora 
• the colonization potential of probiotic supplementation in 
UC as well as its influence on immune function, intestinal perme- 
ability. endotoxemia, and antibodies to flora and food antigens 
• influence of a hypoallergenic diet on circulating lgG levels 
to specific food antigens, followed by evaluation of levels with food 
reintroduction 
• effects of various nutritional supplements such as zinc, 
glutamine, folate, and vitamin A on mucosa! nutritional status, 
secretory IgA, histologic measures, intestinal permeability, and 
endotoxin levels 
• other potentially important interrelationships 
Because of these varied interrelationships, there may be sub- 
sets of UC patients who may be more affected by some intermedi- 
ary factors than by others. The most effective nutritional regimen 
may need to be uniquely developed for each UC patient based on 
reliable measures of these intermediary factors. Also, there may be 
many more dietary factors and nutritional or herbal supplements 
that may be helpful in UC; these should be examined. The model 
itself may need to be enlarged beyond nutrition to include other 
factors such as stress as well as other modalities such as relaxation 
techniques, acupuncture, and homeopathy. 
It would be counterintuitive to suggest that diet and nutri- 
tional supplementation do not influence UC. Whereas research 
has not supported such an association, no thorough or compre- 
hensive investigations have been conducted to better under- 
stand the causes, contributing factors, or range of potentially 
beneficial therapeutic approaches. This presents the CAM com- 
munity with an opportunity to show that CAM treatments are 
significantly helpful and that the CAM model of healthcare is 
more preventive, less prone to side effects or complications, and 
includes more patient involvement and responsibility than does 
a conventional approach. Conducting this important research 
for UC will be generally helpful if the research model can then be 
applied to other chronic diseases as well. 
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